Cargando…

The unattainable criteria for new infant vaccines

Background. In 2013, the US Advisory Committee on Immunization Practices (ACIP) opted against adding meningococcal vaccines to the infant schedule due to poor cost-effectiveness. This raises a policy question: if meningococcal disease is too rare to justify routine vaccination, are there other vacci...

Descripción completa

Detalles Bibliográficos
Autores principales: Gill, Christopher J., Hodsdon, Lauren, Santosham, Mathuram, O'Brien, Katherine L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989892/
https://www.ncbi.nlm.nih.gov/pubmed/28509601
http://dx.doi.org/10.1080/21645515.2017.1328334
_version_ 1783329537343356928
author Gill, Christopher J.
Hodsdon, Lauren
Santosham, Mathuram
O'Brien, Katherine L.
author_facet Gill, Christopher J.
Hodsdon, Lauren
Santosham, Mathuram
O'Brien, Katherine L.
author_sort Gill, Christopher J.
collection PubMed
description Background. In 2013, the US Advisory Committee on Immunization Practices (ACIP) opted against adding meningococcal vaccines to the infant schedule due to poor cost-effectiveness. This raises a policy question: if meningococcal disease is too rare to justify routine vaccination, are there other vaccine-preventable causes of US infant deaths that could be supported? Methods. We tabulated US infant deaths from 2009–2013 using the CDC WONDER database. These causes of death were then categorized into one of 3 categories: 1) vaccine-preventable using currently available interventions; 2) potentially vaccine-preventable within the next 10 years; and 3) not preventable. Results. From 19.8 million births (3.9 million/year), ∼122,000 infants died (0.62%). Of these, 181 (0.15% of all deaths) were preventable using currently available vaccines, while an additional 779 were categorized as potentially preventable in the next 10 y. By exclusion, 121,040 (99.2%) were judged ‘not vaccine-preventable’. Meningococcal deaths contributed at most 0.03% of all infant deaths, but accounted for 17–34% of current vaccine-preventable deaths. Conclusions. The low number of vaccine-preventable deaths in the US makes it increasingly difficult to justify the introduction of any new infant vaccines.
format Online
Article
Text
id pubmed-5989892
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-59898922018-06-07 The unattainable criteria for new infant vaccines Gill, Christopher J. Hodsdon, Lauren Santosham, Mathuram O'Brien, Katherine L. Hum Vaccin Immunother Commentary Background. In 2013, the US Advisory Committee on Immunization Practices (ACIP) opted against adding meningococcal vaccines to the infant schedule due to poor cost-effectiveness. This raises a policy question: if meningococcal disease is too rare to justify routine vaccination, are there other vaccine-preventable causes of US infant deaths that could be supported? Methods. We tabulated US infant deaths from 2009–2013 using the CDC WONDER database. These causes of death were then categorized into one of 3 categories: 1) vaccine-preventable using currently available interventions; 2) potentially vaccine-preventable within the next 10 years; and 3) not preventable. Results. From 19.8 million births (3.9 million/year), ∼122,000 infants died (0.62%). Of these, 181 (0.15% of all deaths) were preventable using currently available vaccines, while an additional 779 were categorized as potentially preventable in the next 10 y. By exclusion, 121,040 (99.2%) were judged ‘not vaccine-preventable’. Meningococcal deaths contributed at most 0.03% of all infant deaths, but accounted for 17–34% of current vaccine-preventable deaths. Conclusions. The low number of vaccine-preventable deaths in the US makes it increasingly difficult to justify the introduction of any new infant vaccines. Taylor & Francis 2017-06-19 /pmc/articles/PMC5989892/ /pubmed/28509601 http://dx.doi.org/10.1080/21645515.2017.1328334 Text en © 2018 The Author(s). Published with license by Taylor and Francis http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Commentary
Gill, Christopher J.
Hodsdon, Lauren
Santosham, Mathuram
O'Brien, Katherine L.
The unattainable criteria for new infant vaccines
title The unattainable criteria for new infant vaccines
title_full The unattainable criteria for new infant vaccines
title_fullStr The unattainable criteria for new infant vaccines
title_full_unstemmed The unattainable criteria for new infant vaccines
title_short The unattainable criteria for new infant vaccines
title_sort unattainable criteria for new infant vaccines
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989892/
https://www.ncbi.nlm.nih.gov/pubmed/28509601
http://dx.doi.org/10.1080/21645515.2017.1328334
work_keys_str_mv AT gillchristopherj theunattainablecriteriafornewinfantvaccines
AT hodsdonlauren theunattainablecriteriafornewinfantvaccines
AT santoshammathuram theunattainablecriteriafornewinfantvaccines
AT obrienkatherinel theunattainablecriteriafornewinfantvaccines
AT gillchristopherj unattainablecriteriafornewinfantvaccines
AT hodsdonlauren unattainablecriteriafornewinfantvaccines
AT santoshammathuram unattainablecriteriafornewinfantvaccines
AT obrienkatherinel unattainablecriteriafornewinfantvaccines